Bristol-Myers Squibb Co (NYSE:BMY)’s traded shares stood at 3.72 million during the last session, with the company’s beta value hitting 0.45. At the last check today, the stock’s price was $56.82, to imply a decrease of -2.87% or -$1.68 in intraday trading. The BMY share’s 52-week high remains $61.08, putting it -7.5% down since that peak but still an impressive 30.75% since price per share fell to its 52-week low of $39.35. The company has a valuation of $115.24B, with an average of 13.18 million shares in intraday trading volume over the past 10 days and average of 10.83 million shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for Bristol-Myers Squibb Co (BMY), translating to a mean rating of 2.70. Of 14 analyst(s) looking at the stock, 0 analyst(s) give BMY a Sell rating. 0 of those analysts rate the stock as Overweight while 9 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 1.48.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Bristol-Myers Squibb Co (NYSE:BMY) trade information
After registering a -2.87% downside in the latest session, Bristol-Myers Squibb Co (BMY) has traded red over the past five days. The 5-day price performance for the stock is 4.95%, and 6.84% over 30 days. With these gigs, the year-to-date price performance is 10.74%. Short interest in Bristol-Myers Squibb Co (NYSE:BMY) saw shorts transact 23.42 million shares and set a 2.3 days time to cover.
The extremes give us $41 and $85 for target low and target high price respectively. As such, BMY has been trading -49.6% off suggested target high and 27.84% from its likely low.
Bristol-Myers Squibb Co (BMY) estimates and forecasts
Looking at statistics comparing Bristol-Myers Squibb Co share performance against respective industry, we note that the company has underperformed competitors. Bristol-Myers Squibb Co (BMY) shares are 29.05% up over the last 6 months, with its year-to-date growth rate lower than industry average at -88.02% against 17.70%. Revenue is forecast to shrink -13.19% this quarter before jumping 142.49% for the next one. The rating firms project that company’s revenue will grow 5.41% compared to the previous financial year.
Revenue forecast for the current quarter as set by 19 analysts is 11.54B. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 11.67B.Earnings reports from the last fiscal year show that sales brought in 11.48B and 11.87B respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 0.53% before dropping -1.61% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 5.14% for the past 5-year period. While 2024 is set for a -88.13% return in earnings, projections for the next 5 years are at -3.66% annually.
BMY Dividends
Bristol-Myers Squibb Co has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Bristol-Myers Squibb Co has a forward dividend ratio of 2.40, with the share yield ticking at 4.22% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 3.41%.
Bristol-Myers Squibb Co (NYSE:BMY)’s Major holders
Bristol-Myers Squibb Co insiders hold 0.11% of total outstanding shares, with institutional holders owning 78.50% of the shares at 78.59% float percentage. In total, 78.50% institutions holds shares in the company, led by VANGUARD GROUP INC. As of 2024-06-30, the company held over 186.57 million shares (or 9.2225% of shares), all amounting to roughly $7.75 billion.
The next major institution holding the largest number of shares is BLACKROCK INC. with 158.66 million shares, or about 7.8428% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $6.59 billion.
